Kibow Biotech to Educate the Educators on Renadyl™ Probiotics for Kidney Health Applications at AADE Conference in Philadelphia, PA

News provided by

Aug 06, 2013, 08:30 ET

NEWTOWN SQUARE, Pa., Aug. 6, 2013 /PRNewswire/ -- Kibow Biotech will present Renadyl™, the Company's probiotic formulation for kidney health, at the American Association of Diabetic Educators (AADE) Conference, to be held from Aug 8–10 at the Philadelphia Convention Center, PA. These educators are fully aware that about 50% of their diabetic patients will eventually suffer from chronic kidney failure. Kibow's exhibit staff, including its robotic ambassador (Kibot), will be available to discuss the potential of RENADYL™. The product is the only probiotic dietary supplement to have benefited from the same rigorous R&D and clinical validation procedures as those normally followed for any pharmaceutical. The product has been granted composition and utility patents in USA (7), Canada (2), Australia (2), Japan (1), Korea (1), and India (2) and has a patent pending status in Europe. Adhering to US FDA's Generally Recognized as Safe (GRAS) status on probiotics, RENADYL™ is presently sold primarily in the USA and Canada via Kibow's on-line store (www.renadyl.com). In the USA and in various overseas countries, the results of clinical trials involving patients in various stages of Chronic Kidney Disease including stages III and IV (predialysis) and End Stage Renal Disease (ESRD or dialysis patients), confirmed the product's safety and ability to complement kidney function with the novel concept of "Enteric Uremic Toxin Reduction Technology" for those with renal dysfunction or related conditions.

About Kibow Biotech: Founded in Oct 1, 1997 in Philadelphia, Kibow Biotech specializes in research, development and commercialization of probiotic dietary supplements adhering to US FDA and FTC regulations. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health and other healthcare applications. The Company's flagship product, Renadyl™, is currently marketed in the U.S. and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.

About Enteric Uremic Toxin Reduction Technology: Kibow's novel "enteric uremic toxin reduction technology" addresses the accumulation of various uremic toxins which diffuse into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for humans) and Azodyl® (veterinary formulation) consist of a combination of three specific probiotic microbial strains. The results of various clinical trials, including the latest conducted in 2012, have provided encouraging preliminary evidence that the Company's technology could be effective when the product formulation is taken regularly according to medical directives and in a context of standard care as dictated by individual conditions.

Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the current status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug or food supplement in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a prevention product or therapy. The dietary supplement formulation of Renadyl™ will not cure, prevent or mitigate any disease. Other factors that could cause or contribute to differences in actual results include, but are not limited to, risks associated with any future clinical trials of product candidates, the possibility that testing may reveal to be undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

For further information, contact Dr. Natarajan Ranganathan: CSR - (610) 353 5130 or [email protected]

SOURCE Kibow Biotech